Christopher Missling - Sep 11, 2025 Form 4 Insider Report for ANAVEX LIFE SCIENCES CORP. (AVXL)

Role
President and CEO, Director
Signature
/s/Christopher Missling
Stock symbol
AVXL
Transactions as of
Sep 11, 2025
Transactions value $
-$444,560
Form type
4
Date filed
9/12/2025, 07:00 PM
Previous filing
Aug 22, 2025
Next filing
Oct 3, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
MISSLING CHRISTOPHER U President and CEO, Director 630 5TH AVENUE, 20TH FLOOR, NEW YORK /s/Christopher Missling 2025-09-12 0001196573

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVXL Common Stock Options Exercise $945K +188K +12.77% $5.04 1.66M Sep 11, 2025 Direct
transaction AVXL Common Stock Tax liability -$1.39M -145K -8.76% $9.58 1.51M Sep 11, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVXL Stock Option (Right to Buy) Options Exercise $0 -188K -100% $0.00 0 Sep 11, 2025 Common Stock 188K $5.04 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a "net exercise" of outstanding stock options, which options were scheduled to expire on September 18, 2025. The reporting person received 42,452 shares of common stock on net exercise of an option to purchase 187,500 shares of common stock. The Company withheld 145,048 shares of common stock underlying the option as consideration for the exercise price and tax withholdings, using the closing price on September 11, 2025 of $9.58, pursuant to the terms of the Company's 2015 Stock Option Plan.